Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 3;12(1):367.
doi: 10.3390/jcm12010367.

Juvenile Psoriatic Arthritis: Myth or Reality? An Unending Debate

Roberta Naddei  1 , Ana Rebollo-Giménez  2 , Marco Burrone  3   4 , Valentina Natoli  4 , Silvia Rosina  2 , Alessandro Consolaro  2   4 , Angelo Ravelli  4   5
Affiliations
Review

Juvenile Psoriatic Arthritis: Myth or Reality? An Unending Debate

Roberta Naddei et al. J Clin Med. .

Abstract

Juvenile psoriatic arthritis (JPsA) accounts for 1-7% of all cases of juvenile idiopathic arthritis (JIA) and its definition has been a matter of controversy among pediatric rheumatologists for many years. The traditional attribution of JPsA to the spondyloarthropathy group was challenged in the early 1990s, whereas the recent demonstrations of its heterogenous nature have led to questions about its identification as a distinct category in JIA classification. It has been shown that children with the phenotype of JPsA can be divided in two subgroups, one presenting with the features of early-onset ANA-positive JIA, and another that belongs to the spectrum of spondyloarthropathies. The few studies that have compared the clinical characteristics and genetic determinants of JPsA with those of the other JIA categories have obtained contrasting findings. The debate on the categorization of JPsA as a distinct entity within JIA classification is still ongoing and has prompted the revision of its current classification.

Keywords: childhood arthritis; classification; juvenile idiopathic arthritis; juvenile psoriatic arthritis; psoriasis.

PubMed Disclaimer

Conflict of interest statement

R.N., A.R.G., M.B., V.N. and S.R. declare no conflict of interest. A.C. reports an Investigator initiated research grant from Pfizer and Alfa Sigma and speaker’s bureaus from Pfizer and Abbvie. A.R. declares that he received speaker’s bureau, honoraria for consultancy and/or research grants from Abbvie, Alexion, Angelini, BMS, Novartis, Pfizer, Reckitt-Benkiser, Roche, and SOBI.

Figures

Figure 1
Figure 1
Psoriatic skin lesion in a child with JPsA.
Figure 2
Figure 2
Nail changes in a child with JPsA.
See this image and copyright information in PMC

References

    1. Martini A., Lovell D.J., Albani S., Brunner H.I., Hyrich K.L., Thompson S.D., Ruperto N. Juvenile idiopathic arthritis. Nat. Rev. Dis. Primers. 2022;8:5. doi: 10.1038/s41572-021-00332-8. - DOI - PubMed
    1. Prakken B., Albani S., Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138–2149. doi: 10.1016/S0140-6736(11)60244-4. - DOI - PubMed
    1. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–778. doi: 10.1016/S0140-6736(07)60363-8. - DOI - PubMed
    1. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., He X., Maldonado-Cocco J., Orozco-Alcala J., Prieur A.M., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J. Rheumatol. 2004;31:390–392. - PubMed
    1. Consolaro A., Giancane G., Alongi A., van Dijkhuizen E.H.P., Aggarwal A., Al-Mayouf S.M., Bovis F., De Inocencio J., Demirkaya E., Flato B., et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: An observational cohort study. Lancet Child Adolesc. Health. 2019;3:255–263. doi: 10.1016/S2352-4642(19)30027-6. - DOI - PubMed

LinkOut - more resources